Don't bother listening to the trash or to any more
Post# of 15624
(Total Views: 324)
Posted On: 04/20/2017 7:17:47 AM
Don't bother listening to the trash or to any more BS about how little the company has spent on R&D.
Yes we all know that R & D in the medical field is prohibitively expensive. OWCP knows this as well and this is why they have wisely entered into collaborative agreements with leading Israeli hospitals and scientific institutions.
http://www.marketwatch.com/story/10-q-owc-pha...2016-08-29
What does OWCP give up for this collaborative arrangement?
In my opinion the above is a fair arrangement. Mind you the company still has to pay something for this:
The other reason why the R & D expenses are lower is because of the in-house medical team that the company has. The likes of Dr. Baruch are motivated not by the monthly salary that they receive; rather, it's the incentives such as the stock options awarded to them. The same applies to the others on the team.
Yes we all know that R & D in the medical field is prohibitively expensive. OWCP knows this as well and this is why they have wisely entered into collaborative agreements with leading Israeli hospitals and scientific institutions.
http://www.marketwatch.com/story/10-q-owc-pha...2016-08-29
What does OWCP give up for this collaborative arrangement?
Quote:
While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis .
In my opinion the above is a fair arrangement. Mind you the company still has to pay something for this:
Quote:
Pursuant to the collaboration agreements, we are obliged to pay Sheba $300,000 throughout 2016 for conducting the psoriasis research, and $100,000 for the fibromyalgia research during the two years of the study. We currently have the financial resources to fund our obligations under these agreements, but anticipate that we will require additional funding during the next 12 months for our continuing and planned expanded operations.
The other reason why the R & D expenses are lower is because of the in-house medical team that the company has. The likes of Dr. Baruch are motivated not by the monthly salary that they receive; rather, it's the incentives such as the stock options awarded to them. The same applies to the others on the team.
(1)
(0)